Ep. 30 - Gilead's Merdad Parsey скачать в хорошем качестве

Ep. 30 - Gilead's Merdad Parsey

The days of incremental benefit are numbered, and drug developers have to bring something that will move the needle significantly to bring meaningful benefit to patients, Gilead CMO Merdad Parsey told #TheBioCenturyShow. That’s the consequence of the success the industry has had, which has raised the bar and changed the strategy for how drugs are developed. In conversation with Editor in Chief Simone Fishburn, Parsey also discussed the challenges facing small biotechs who must now meet requirements — such as diversity in clinical trials or dose optimization studies for some cancer treatments — which can be burdensome from a cost and logistics perspective. He also outlined the strategy for Gilead in R&D, in particular how it plans to grow its oncology pipeline and what its priorities are in HIV. View full story: https://www.biocentury.com/article/64... ‪@GileadSciencesInc‬ #biotech #pharma #biopharma #gileadsciences 00:00 - Intro 01:20 – Growing Oncology 10:50 – Checkpoint Hurdles 14:30 – What’s Next for CAR Ts 19:30 – Unmet Need in HIV 23:50 – Challenges for Small Biotechs